Objective To explore the efficacy and safety of amisulpride vs .loxapin succinate in the treat-ment of first-episode schizophrenia .Methods Sixty-five first-episode schizophrenics were randomly as-signed to two groups took orally amisulpride or loxapin succinate for 6 weeks .Before and after treatment efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS ) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total scores of the PANSS of both groups lowered continuously compared with pretreatment (P<0 .01);at the end of the 6th week obvious effective and effective rate were respectively 80 .0% and 93 .3% in research and 76 .7% and 90 .0% in control group ,which showed no significant differences (P>0 .05) .Adverse reactions of both groups were mild ,tremor incidence was significantly lower in research than control group (χ2 =4 .04 ,P<0 .05) ,and there were no significant group differences in incidences of other adverse reactions (P>0 .05) . Conclusion Amisulpride has an efficacy equivalent to loxapin succinate ,but the former has higher safety and better compliance .%目的：探讨氨磺必利与丁二酸洛沙平治疗首发精神分裂症患者的临床疗效和安全性。方法将65例首发精神分裂症患者随机分为两组，分别口服氨磺必利与丁二酸洛沙平治疗，观察6周。治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分均较治疗前呈持续性下降（P＜0．01）；治疗6周末研究组显效率80．0％、有效率93．3％，对照组分别为76．7％、90．0％，两组比较差异无显著性（ P＞0．05）。两组不良反应均较轻，研究组震颤发生率显著低于对照组（χ2＝4．04，P＜0．05），其他不良反应与对照组比较差异无显著性（P＞0．05）。结论氨磺必利与丁二酸洛沙平治疗首发精神分裂症疗效显著且相当，但氨磺必利安全性更高，依从性更好。
展开▼
